Review




Structured Review

KoBioLabs Inc oral probiotic kbl697
Oral microbial therapy studies on efficacy and adverse effects of oral therapies in psoriasis.
Oral Probiotic Kbl697, supplied by KoBioLabs Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/oral probiotic kbl697/product/KoBioLabs Inc
Average 90 stars, based on 1 article reviews
oral probiotic kbl697 - by Bioz Stars, 2026-03
90/100 stars

Images

1) Product Images from "New and emerging oral therapies for psoriasis"

Article Title: New and emerging oral therapies for psoriasis

Journal: Drugs in Context

doi: 10.7573/dic.2024-5-6

Oral microbial therapy studies on efficacy and adverse effects of oral therapies in psoriasis.
Figure Legend Snippet: Oral microbial therapy studies on efficacy and adverse effects of oral therapies in psoriasis.

Techniques Used: Clinical Proteomics



Similar Products

90
KoBioLabs Inc oral probiotic kbl697
Oral microbial therapy studies on efficacy and adverse effects of oral therapies in psoriasis.
Oral Probiotic Kbl697, supplied by KoBioLabs Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/oral probiotic kbl697/product/KoBioLabs Inc
Average 90 stars, based on 1 article reviews
oral probiotic kbl697 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Oral microbial therapy studies on efficacy and adverse effects of oral therapies in psoriasis.

Journal: Drugs in Context

Article Title: New and emerging oral therapies for psoriasis

doi: 10.7573/dic.2024-5-6

Figure Lengend Snippet: Oral microbial therapy studies on efficacy and adverse effects of oral therapies in psoriasis.

Article Snippet: KBL697 is an oral probiotic developed by the South Korean biotechnology company KoBioLabs from a strain of the bacterium Lactobacillus gasseri , which, unlike EDP1815, is a live agent, directly altering the gut microbiome.

Techniques: Clinical Proteomics